Indicator, Reagent, or Diagnostic Aid – Page 3

Bristol Myers Squibb Resumes Radiopharmaceutical Phase 3 Trial Following Isotope Shortage

12 months ago talkbio0Tagged actinium-225, Isotopes, Myers, Phase 3 trial, Radiopharmaceuticals, RYZ101, shortage, squibb

Bristol Myers Squibb, Radiopharmaceutical, Phase 3 Trial, Isotope Shortage, RYZ101, Actinium-225

Gan & Lee Pharmaceuticals Unveils Promising Mid-Stage Data for Homegrown Obesity Drug

1 year ago talkbio0Tagged Clinical Trials, gallium nitrate, Glucagon-Like Peptide 1, mid-stage, Obesity, Weight Loss

Gan & Lee Pharmaceuticals, Obesity Drug, Mid-Stage Data, Clinical Trial, Weight Loss, GLP-1

Lilly Secures Option to Acquire Radionetics for $1 Billion in Radiopharma Deal

1 year ago talkbio0Tagged Acquisition (action), Biotechnology, Eli, Eli Lilly, Neoplasms, Radionetics, Radiopharmaceuticals, Solid Neoplasm

Eli Lilly, Radionetics Oncology, Radiopharmaceuticals, G Protein-Coupled Receptors, Solid Tumors, Biotechnology, Acquisition

J&J’s Tremfya Fails to Meet Primary Endpoint in Giant Cell Arteritis Trial

1 year ago talkbio0Tagged Giant Cell Arteritis, glucocorticoid-free remission, Johnson & Johnson, Phase 2 Clinical Trials, Primary Endpoint, Tremfya

Tremfya, Johnson & Johnson, Giant Cell Arteritis, Phase II Trial, Primary Endpoint, Glucocorticoid-Free Remission

Jazz Pharmaceuticals’ Essential Tremor Drug Candidate Fails to Meet Primary Endpoint in Phase IIb Trial

1 year ago talkbio0Tagged calcium channel modulator, Essential Tremor, Jazz, Phase II B Trial, Primary Endpoint

Jazz Pharmaceuticals, suvecaltamide, essential tremor, phase IIb trial, primary endpoint, calcium channel modulator

Aerovate Therapeutics’ Shares Plummet 93.3% After Disappointing IMPAHCT Study Results for AV-101 in Pulmonary Arterial Hypertension

1 year ago talkbio0Tagged 4-aminohippuric acid, Aerovate, AV-101, Biotech Stocks, Clinical Trials, Drug Formulation Process, imatinib, IMPAHCT, Inspiration function, Pulmonary arterial hypertension

Aerovate Therapeutics, AV-101, IMPAHCT Study, Pulmonary Arterial Hypertension, PAH, Imatinib, Inhaled Formulation, Biotech Stocks, Clinical Trials

Telix Pharmaceuticals Aims for $200 Million IPO in Radiopharmaceuticals Market Amid Slowing Biotech Nasdaq Offerings

1 year ago talkbio0Tagged biotech, IPO, Nasdaq, offerings, Radiopharmaceuticals, Telix

Telix Pharmaceuticals, Radiopharmaceuticals, IPO, Biotech, Nasdaq Offerings

ITM Secures €188 Million to Enhance Radiopharmaceutical Pipeline and Strengthen Medical Radioisotope Manufacturing

1 year ago talkbio0Tagged actinium-225, Authority, BlackRock, cancer pipeline, Gastro-enteropancreatic neuroendocrine tumor, Investments, Isotopes, medical radioisotopes, Munich, Qatar, Radiopharmaceuticals, SLC22A18 gene, Technology, Temasek

ITM Isotope Technologies Munich, radiopharmaceutical biotech, Temasek, BlackRock, Qatar Investment Authority, medical radioisotopes, Lutetium-177, Actinium-225, cancer pipeline, gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

RayzeBio Warned of Potential Actinium Isotope Supply Issues Before $4.1B BMS Deal

1 year ago talkbio0Tagged actinium-225, Isotope Supply, Myers, Neoplasms, Neurosecretory Systems, Radiopharmaceuticals, RayzeBio, squibb

RayzeBio, Bristol Myers Squibb, Actinium-225, Isotope Supply Issues, Radiopharmaceuticals, Neuroendocrine Tumors

Annexon Shares Soar as ANX005 Meets Primary Endpoint in Phase 3 Trial for Guillain-Barré Syndrome

1 year ago talkbio0Tagged Annexon, ANX005, Disability, Guillain-Barre Syndrome, Phase 3 trial, Prices, Primary Endpoint, Sharing (Social Behavior), surge

Annexon, ANX005, Guillain-Barré Syndrome, Phase 3 Trial, Primary Endpoint, Disability Reduction, Share Price Surge